Affinity Asset Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Affinity Asset Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-258,115	Closed	-$5.05M	–	84
2022 Q4	$5.05M	Sell	258,115 -9,679	-4%	-$178K	1.98%	19
2022 Q3	$4.27M	Buy	267,794 +17,328	+7%	+$270K	1.19%	26
2022 Q2	$3.45M	Sell	250,466 -49,534	-17%	-$590K	1.45%	27
2022 Q1	$4.76M	Buy	300,000 +135,000	+82%	+$2.33M	0.76%	23
2021 Q4	$3.6M	Buy	165,000 +84,772	+106%	+$2.31M	1.31%	32
2021 Q3	$2.4M	Sell	80,228 -39,772	-33%	-$1.45M	0.61%	36
2021 Q2	$5.32M	Buy	120,000 +35,000	+41%	+$1.52M	1.9%	15
2021 Q1	$3.77M	Sell	85,000 -20,000	-19%	-$1.1M	1.28%	18
2020 Q4	$5.76M	Buy	+105,000	New	+$3.83M	3.05%	7

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Affinity Asset Advisors's RCKT Position: Q1 2023 in Review

Affinity Asset Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 258,115 shares — an estimated $5.05M sold.

Affinity Asset Advisors first reported a position in RCKT in Q4 2020 and held it in 9 quarters. The position peaked at $5.76M in Q4 2020. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

Affinity Asset Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Affinity Asset Advisors sold 258,115 Rocket Pharmaceuticals shares in Q1 2023, an estimated $5.05M.
Affinity Asset Advisors first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Affinity Asset Advisors's Rocket Pharmaceuticals position peaked at $5.76M in Q4 2020.
163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.